Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2018 Dec 4. pii: CD-18-1119. doi: 10.1158/2159-8290.CD-18-1119. [Epub ahead of print]

PMID:
30514704
2.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
3.

Mapping buried nanostructures using subsurface ultrasonic resonance force microscopy.

van Es MH, Mohtashami A, Thijssen RMT, Piras D, van Neer PLMJ, Sadeghian H.

Ultramicroscopy. 2018 Jan;184(Pt A):209-216. doi: 10.1016/j.ultramic.2017.09.005. Epub 2017 Sep 23.

PMID:
28968522
4.

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.

Slinger E, Thijssen R, Kater AP, Eldering E.

Leukemia. 2017 Dec;31(12):2601-2607. doi: 10.1038/leu.2017.129. Epub 2017 May 2.

PMID:
28462919
5.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
6.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP.

Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

7.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
8.

Robustness of plasmon phased array nanoantennas to disorder.

Arango FB, Thijssen R, Brenny B, Coenen T, Koenderink AF.

Sci Rep. 2015 Jun 3;5:10911. doi: 10.1038/srep10911.

9.

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E.

Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8. No abstract available.

10.

Plasmomechanical Resonators Based on Dimer Nanoantennas.

Thijssen R, Kippenberg TJ, Polman A, Verhagen E.

Nano Lett. 2015 Jun 10;15(6):3971-6. doi: 10.1021/acs.nanolett.5b00858. Epub 2015 May 7.

PMID:
25938170
11.

Parallel Transduction of Nanomechanical Motion Using Plasmonic Resonators.

Thijssen R, Kippenberg TJ, Polman A, Verhagen E.

ACS Photonics. 2014 Nov 19;1(11):1181-1188. Epub 2014 Oct 7.

12.

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, van Attekum MH, van Bochove GG, Luijks DM, Pals ST, van Lier RA, Kater AP, van Oers MH, Eldering E.

Blood. 2013 Oct 24;122(17):3010-9. doi: 10.1182/blood-2012-11-467670. Epub 2013 Sep 6.

13.

CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.

Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E.

Cell Death Dis. 2013 Aug 29;4:e782. doi: 10.1038/cddis.2013.305.

14.

Plasmon nanomechanical coupling for nanoscale transduction.

Thijssen R, Verhagen E, Kippenberg TJ, Polman A.

Nano Lett. 2013 Jul 10;13(7):3293-7. doi: 10.1021/nl4015028. Epub 2013 Jun 11.

PMID:
23746212
15.

Experience with shared decision making in gynaecological practice: treatment decisions in patients with dysfunctional uterine blood loss.

van der Wilt GJ, Meulendijks CF, Thijssen RF.

Eur J Obstet Gynecol Reprod Biol. 2005 Jun 1;120(2):210-6.

PMID:
15925055
16.

Radiofrequency induced endometrial ablation: an update.

Thijssen RF.

Br J Obstet Gynaecol. 1997 May;104(5):608-13.

PMID:
9166206
17.

[Non-hysteroscopic thermodestruction of the endometrium using radio waves in the treatment of menorrhagia].

Thijssen RF, Dony JM, Rolland R.

Ned Tijdschr Geneeskd. 1993 Aug 28;137(35):1776-80. Dutch.

PMID:
8371823
18.

Avian herpesvirus as a live viral vector for the expression of heterologous antigens.

Sondermeijer PJ, Claessens JA, Jenniskens PE, Mockett AP, Thijssen RA, Willemse MJ, Morgan RW.

Vaccine. 1993;11(3):349-58.

PMID:
8383385
19.

Successful pregnancy after ZIFT in a patient with congenital cervical atresia.

Thijssen RF, Hollanders JM, Willemsen WN, van der Heyden PM, van Dongen PW, Rolland R.

Obstet Gynecol. 1990 Nov;76(5 Pt 2):902-4.

PMID:
2216251
20.

Is there influence of smoking on the mutagenicity of follicular fluid?

Bos RP, van Heijst CH, Hollanders HM, Theuws JL, Thijssen RF, Eskes TK.

Fertil Steril. 1989 Nov;52(5):774-7.

PMID:
2806619
21.

Quantitation of conjugate formation between human polymorphonuclear leukocytes and antibody-coated target cells by flow cytometry: the role of Fc receptor and LFA-1 antigen.

van Kessel KP, van Strijp JA, van der Tol ME, van Kats-Renaud HJ, Thijssen RM, Fluit AC, Verhoef J.

J Leukoc Biol. 1989 Nov;46(5):467-75.

PMID:
2681490
22.

Eating, drinking, and cycling. A controlled Tour de France simulation study, Part II. Effect of diet manipulation.

Brouns F, Saris WH, Stroecken J, Beckers E, Thijssen R, Rehrer NJ, ten Hoor F.

Int J Sports Med. 1989 May;10 Suppl 1:S41-8. Review.

PMID:
2663742
23.

Eating, drinking, and cycling. A controlled Tour de France simulation study, Part I.

Brouns F, Saris WH, Stroecken J, Beckers E, Thijssen R, Rehrer NJ, ten Hoor F.

Int J Sports Med. 1989 May;10 Suppl 1:S32-40. Review.

PMID:
2663741
24.

Serological classification of recent infectious bronchitis virus isolates by the neutralization of immunofluorescent FOCI.

Csermelyi M, Thijssen R, Orthel F, Burger AG, Kouwenhoven B, Lutticken D.

Avian Pathol. 1988;17(1):139-48.

PMID:
18766673
25.

Environmental and hormonal control of the seasonal egg laying period in field specimens of Lymnaea stagnalis.

Dogterom GE, Thijssen R, van Loenhout H.

Gen Comp Endocrinol. 1985 Jan;57(1):37-42.

PMID:
3972243
26.

Effects of lysosomotropic amines on human polymorphonuclear leucocyte function.

Vandenbroucke-Grauls CM, Thijssen RM, Marcelis JH, Sharma SD, Verhoef J.

Immunology. 1984 Feb;51(2):319-26.

Supplemental Content

Loading ...
Support Center